Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group (Q35016059)

5 August 2017

title

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group (English)

1 reference

5 August 2017

10

1 reference

5 August 2017

12

Pierre Laurent-Puig

0 references

author name string

Jean-François Emile

1

1 reference

5 August 2017

Julie Tisserand

2

1 reference

5 August 2017

Loic Bergougnoux

3

1 reference

5 August 2017

Frédérique Nowak

4

1 reference

5 August 2017

Gladwys Faucher

5

1 reference

5 August 2017

Sylvie Surel

6

1 reference

5 August 2017

Aude Lamy

7

1 reference

5 August 2017

Delphine Lecorre

8

1 reference

5 August 2017

Zofia Helias-Rodzewicz

9

1 reference

5 August 2017

Jean-Christophe Sabourin

11

1 reference

5 August 2017

BRAF EQA Group

13

1 reference

5 August 2017

language of work or name

English

0 references

publication date

11 October 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

13

1 reference

5 August 2017

page(s)

472

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-13-472

5 August 2017

exact match

0 references

cites work

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Improved survival with MEK inhibition in BRAF-mutated melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852250

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

Tumour molecular profiling for deciding therapy-the French initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

Reducing Sequence Artifacts in Amplicon-Based Massively Parallel Sequencing of Formalin-Fixed Paraffin-Embedded DNA by Enzymatic Depletion of Uracil-Containing Templates

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-472

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24119386

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-13-472

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference